TIGIT - Wikipedia
网页TIGIT (/ ˈ t ɪ dʒ ɪ t / TIJ-it; [5] also called T cell immunoreceptor with Ig and ITIM domains) is an immune receptor present on some T cells and natural killer cells (NK). [6] It is also identified as WUCAM [7] and Vstm3. [8] TIGIT could bind to CD155 (PVR) on dendritic cells (DCs), macrophages, etc. with high affinity, and also to CD112 ...
TIGIT靶点概况与研发动态 - 知乎 - 知乎专栏
网页tigit是近年来新发现的一种具有免疫抑制功能的细胞表面蛋白，本文将就tigit蛋白的功能及药物开发现状进行回顾和总结。 相对于PD-1、PD-L1、CTLA-4等免疫检查点而言，TIGIT发现的时间较短，是一个比较新的分子。
TIGIT, a novel immune checkpoint therapy for melanoma
网页2023年7月26日 · This review mainly describes the immunosuppressive mechanism of TIGIT and its role in antitumor immunity of melanoma, so as to provide new ideas and schemes for the clinical treatment of melanoma...
TIGIT---未来抗癌神药的热门靶点 - 知乎 - 知乎专栏
网页TIGIT---未来抗癌神药的热门靶点. 免疫治疗现已成为肿瘤治疗不可或缺的一部分，其中免疫检查点抑制剂更是备受关注。. 近年来，药监局对免疫检查点抑制剂药物大开绿灯，经典靶点PD-1抑制剂 Opdivo和Keytruda (进口)从递交申请到获批上市都历时不到一年，而国产 ...
TIGIT as an emerging immune checkpoint - PubMed
网页T cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on lymphocytes that was recently propelled under the spotlight as a major emerging target in cancer immunotherapy. TIGIT interacts with CD155 expressed on antigen-presenting cells or tumour cells to down-regulate T cell and natural killer (NK) cell functions.
TIGIT as an emerging immune checkpoint - PMC - National …
网页2019年12月25日 · TIGIT is an emerging immune checkpoint that inhibits immune cell responses at multiple steps of the cancer‐immunity cycle. TIGIT impairs T cell priming by dendritic cells, prevents tumour cell killing by Natural Killer cells and cytotoxic T cells, and enhances the immune suppressive activity of regulatory T cells.
【杰论系列】免疫治疗靶点后起之秀：TIGIT - 知乎
网页免疫治疗靶点后起之秀：TIGIT. 免疫检查点抑制剂已经成为癌症治疗的热门领域，其中以PD-1/PD-L1抑制剂为代表，已引起国内外药企的竞相布局。. 但PD-1/PD-L1抑制剂在临床应用中仅有少数患者得到良好治疗，而且还出现耐药性及严重不良反应，因此急需找到新的靶 ...
TIGIT：免疫治疗靶点里的勇起之师 - 百度
网页2024年2月18日 · TIGIT：免疫治疗靶点里的勇起之师. 免疫检查点抑制剂已经成为癌症治疗的热门领域，其中以PD-1/PD-L1抑制剂为代表，已引起国内外数百家药企的竞相布局。. 但随着PD-1/PD-L1抑制剂临床应用的不断扩大，不但仅有少数患者得到良好治疗，而且还出现耐药 …
Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical ...
网页2021年9月21日 · TIGIT is a negative regulator of immune response known to bind to PVR ligands with greater affinity and outcompete the costimulatory receptors, CD226 and CD96, expressed on T cells, thereby inhibiting the activation, proliferation, and differentiation of T cells (Figure 1).
TIGIT: An emerging immune checkpoint target for …
网页2023年7月1日 · TIGIT, also called WUCAM, Vstm3, and VSIG9, first identified in 2009 as a member of the poliovirus receptor (PVR) family, is a newly studied immune checkpoint target for immunotherapy.